For the past couple of weeks, it looked as if Amgen (NASDAQ:AMGN) might actually walk away from a deal with Onyx Pharmaceuticals (UNKNOWN:UNKNOWN). Yesterday, however, put an end to the latest biotech buyout drama, after Amgen officially announced that it's acquiring Onyx for $125 a share. In the following video, a segment from The Motley Fool's health-care show Market Checkup, health-care analysts David Williamson and Max Macaluso discuss the rationale behind this acquisition, and how Amgen investors should also watch competition from biotech company Celgene (NASDAQ:CELG).